Leidos Holdings Inc. (NYSE: LDOS) CEO Roger Krone describes his company’s new agreement to combine with Lockheed Martin Corp.’s (NYSE: LMT) Information Systems & Global Solutions business as a landmark moment for the government services space. “I am convinced that this transaction is the kind of event that is often sought after but rarely found,” Krone said in a conference call Tuesday after the $5 billion deal was announced.
Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that it intends to offer, subject to market and other conditions, $200 million aggregate principal amount of convertible senior unsecured notes that will mature on February 1, 2023 (the Notes). The Notes will be offered and sold only to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Novavax also expects to grant the initial purchasers of the Notes an option to purchase up to an additional $30 million aggregate principal amount of the Notes, solely to cover over-allotments.
The Food and Drug Administration aims to ensure hackers can’t remotely access or control medical devices, and it’s asking the private sector to do more to protect those devices.
Earlier this month, FDA issued draft guidance directing manufacturers to conduct “postmarket” evaluation of their devices, ensuring device security vulnerabilities won’t affect clinical performance.
Alexandria is the largest and leading urban office REIT uniquely focused on collaborative science and technology campuses in AAA innovation cluster locations. The firm currently has more than 19 million rentable square feet of operating properties, as well as development and redevelopment projects under construction, with another 11.6 million square feet in near-term and future ground-up development projects. Alexandria was the first to pioneer this niche under CEO Joel Marcus’ vision when he founded the company in 1994. Since then, the firm has established a dominant market presence across the industry in locations such as Greater Boston/Cambridge, San Francisco, New York City, San Diego, Seattle, Maryland and Research Triangle Park.
Stephanie Fertig and Kory Hallett from the National Institutes of Health (NIH) will give an overview of SBIR and STTR Small Business programs at the NIH.
The talk will include:
At the end of their presentation, the speakers will respond to questions from the audience.
If you want to find ways to expand your biomedical startup using NIH funding, you won’t want to miss this webinar!
T. Rowe Price sunk gobs of money into companies such as Cloudera, Dropbox, Apptio and Evernote in recent years, oftentimes at lofty valuations.
Now, the giant mutual fund manager is resetting some of those bets. According to a report in The Information (subscription required), T. Rowe Price has marked down its stakes in a number of companies.
British pharmaceutical firm GlaxoSmithKline is reportedly discussing terms of a medtech joint venture with US chipmaker Qualcomm.
Talks between the two companies to form a partnership to develop medical technology are “preliminary and nothing has been decided”, reports Bloomberg, citing unnamed sources privy to the information. The Financial Times says the deal could be worth as much as $1 billion, and GSK reportedly has hired lawyers to help negotiate the terms of the joint venture with Qualcomm. If confirmed, FT expects the companies “to pool financial and human resources in a joint effort to develop new technology for use in the pharmaceuticals industry.”
May 8 – 11, 2016 – Grand Hyatt Washington DC in Washington, DC
Health Datapalooza is a national conference focused on liberating health data, and bringing together the companies, startups, academics, government agencies, and individuals with the newest and most innovative and effective uses of health data to improve patient outcomes.
Roche will partner with the Lead Discovery Center (LDC) to identify and advance drug discovery projects intended to address diseases of unmet medical need across several areas. The value of the collaboration and the diseases to be addressed were not disclosed by the LDC, which announced the partnership today.
WIB has collaborated with BioProcess International (BPI), the biopharmaceutical industry´s leading scientific publication, to publish a four-part WIB/BPI special report series in 2016. The mission of this special report series is to provide a unique and interactive platform to reach and educate women (and all professionals) working in the life sciences with insight, mentorship, and leadership support through all stages of career development. Each edition of the WIB/BPI special report series will focus on critical issues all biotechnology professionals need to know, understand and manage in order to climb the corporate ladder and achieve the highest levels of leadership.
